Spots Global Cancer Trial Database for MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
Official Title: MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial
Study ID: NCT02135510
Conditions
Study Description
Brief Summary: In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy (MEC).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gemini Ziekenhuis, Den Helder, Noord Holland, Netherlands
Tergooiziekenhuizen, Hilversum, Noord Holland, Netherlands
Medisch Centrum Alkmaar, Alkmaar, Noord-Holland, Netherlands
Ziekenhuis Amstelland, Amstelveen, Noord-Holland, Netherlands
Waterland Ziekenhuis, Purmerend, Noord-Holland, Netherlands
De Heel - Zaans Medisch Centrum, Zaandam, Noord-Holland, Netherlands
Rijnstate, Arnhem, , Netherlands
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
